While several reports have found a higher incidence of brain metastases in patients with EGFR mutant lung cancers, it has never been shown whether this is due to a biologic propensity or simply a result of the longer survival of these patients due to EGFR targeted therapy [24–26]. The gene discussed is EGFR; the disease is lung cancer.